Abstract:Many clinical studies have shown that induction chemotherapy followed by concurrent chemoradiotherapy improved the survival of locally advanced nasopharyngeal carcinoma (NPC). However, it is still unknown that which induction chemotherapy regimen is the optimal choice. This study focused on the comparison of efficacy and toxicities between induction chemotherapy regimen TPF and GP in locally advanced NPC. Between January 2008 and July 2015, patients with locally advanced NPC (clinical stage III-IVb) were retrospectively analyzed. Inclusion criteria were as follows: (1) pathologically confirmed NPC; (2) clinical stage III-IVb according to the 7th edition of the American Joint Committee on Cancer (AJCC) stage criteria; (3) receiving either TPF regimen plus CCRT or GP regimen plus CCRT; (4) radiotherapy was performed using intensity modulated radiation therapy (IMRT). Exclusion criteria were as follows: (1) patients receiving adjuvant chemotherapy; (2) patients with other malignant diseases. The primary endpoint was overall survival (OS). The Secondary endpoints included progression-free survival (PFS), distant metastasis-free survival (DMFS) and locoregional recurrence-free survival (LRFS). The Kaplan-Meier survival curves and log-rank test were used to evaluate the OS, PFS, LRFS, and DMFS of the two groups. Univariate and multivariate analyses were applied to identify the independent prognostic factors. Chi-square test was performed to compare the toxic effects between the two groups. A total of 80 patients treated with TPF regimen plus CCRT and 80 with GP regimen plus CCRT were eligible for this study. After a median follow-up of 47 months (range 8–97months), no differences were observed between the two groups in terms of 3-year OS (86.1% vs. 94.8%, p = 0.123), PFS (81.1% vs. 90.8%, p = 0.224), DMFS (82.3% vs. 94.1%, p = 0.087), or LRFS (93.6% vs.96.1%, p = 0.794). The results of the multivariate Cox proportional hazard analysis showed that the treatment group was not an independent prognostic factor for OS (HR 2.341; 95% CI 0.878–6.241; p = 0.089), PFS (HR 1.814; 95% CI 0.815–4.036; p=0.145), DMFS (HR 2.343; 95%CI 0.942–5.830; p = 0.067), or LRFS (HR 1.243; 95% CI 0.377–4.103; p = 0.721). Clinical stage was an independent prognostic factor affecting OS (HR 0.198; 95 %CI 0.040–0.975; p = 0.046) and PFS (HR 0.224; 95 %CI 0.062–0.810; p = 0.023).There was significant difference in III-IV hepatic toxicity between the two groups (0 vs. 18.6%, p=0.000). No significant differences were observed in bone marrow suppression and kidney dysfunction between the two arms. GP induction chemotherapy plus CCRT achieved similar survival outcomes to those with TPF induction chemotherapy for locally advanced NPC. However, GP regimen increased grade 3–4 hepatic dysfunction compared with TPF induction chemotherapy. More prospective clinical trials are needed to determine the most effective induction chemotherapy regimen for locally advanced NPC.

Assessment of induction chemotherapy regimen TPF vs GP followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: A retrospective cohort study of 160 patients

Assessment of Induction Chemotherapy Regimen TPF Versus GP Followed by Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: A Retrospective Cohort Study

Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin

Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma.

Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma

Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma

Retrospective Analysis of Induction Chemotherapy plus Concurrent Chemoradiotherapy under Intensity-Modulated Radiotherapy Mode for Locally Advanced Nasopharyngeal Carcinoma

Optimal induction chemotherapeutic regimen followed by concurrent chemotherapy plus intensity-modulated radiotherapy as first-line therapy for locoregionally advanced nasopharyngeal carcinoma

Gemcitabine/Cisplatin versus docetaxel, cisplatin and 5-fluorouracil as induction chemotherapy in locally advanced nasopharyngeal carcinoma

Induction chemotherapy followed by radiotherapy and adjuvant chemotherapy for locally advanced nasopharyngeal carcinoma treated

Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study

Induction Chemotherapy Followed by Intensity-Modulated Radiotherapy Versus Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma: A Retrospective Analysis

Gemcitabine and cisplatin versus docetaxel and cisplatin as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma from non-endemic area of China

Long-term results of concurrent chemoradiotherapy for T3/T4 locally advanced nasopharyngeal carcinoma.

Gemcitabine combined with cisplatin vs. taxane, cisplatin, and fluorouracil in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective case-control study

Therapeutic Evaluation of Induction Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma With Low-risk <i>N</i> Stage A Multicenter Retrospective Study From Nonendemic Region of China

Intensity-modulated Radiotherapy Combined with Sequential Cisplatin and Fluorouracil Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma

Comparison of Concurrent Chemoradiation Therapy Plus Induction Chemotherapy with Cisplatin, Fluorouracil and Docetaxel Versus Gemcitabine and Cisplatin in Advanced Nasopharyngeal Carcinoma

Multimodality Management for Locally Advanced Nasopharyngeal Cancer

Systemic Chemotherapy and Sequential Locoregional Radiotherapy in Initially Metastatic Nasopharyngeal Carcinoma: Retrospective Analysis with 821 Cases

1108OChemotherapy plus local-regional radiotherapy versus chemotherapy alone in primary metastatic nasopharyngeal carcinoma: A randomized, open-label, phase III trial